NCT02503774: MEDI9447 Alone and in Combination With MEDI4736 in Adult) Subjects With Select Advanced Solid Tumors

NCT02503774
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 101 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Untreated central nervous system (CNS) metastatic disease
https://ClinicalTrials.gov/show/NCT02503774

Comments are closed.

Up ↑